AVITA Medical, Inc. (NASDAQ:RCEL) CFO Acquires $10,250.00 in Stock

AVITA Medical, Inc. (NASDAQ:RCEL - Get Free Report) CFO David D. O'toole bought 1,000 shares of the company's stock in a transaction dated Wednesday, February 19th. The stock was bought at an average cost of $10.25 per share, with a total value of $10,250.00. Following the completion of the transaction, the chief financial officer now owns 24,734 shares in the company, valued at approximately $253,523.50. This trade represents a 4.21 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

AVITA Medical Stock Down 2.0 %

AVITA Medical stock traded down $0.20 during trading hours on Friday, hitting $9.75. The stock had a trading volume of 259,662 shares, compared to its average volume of 237,967. The stock's 50-day moving average price is $10.40 and its 200-day moving average price is $10.63. AVITA Medical, Inc. has a 12-month low of $7.51 and a 12-month high of $18.93. The stock has a market capitalization of $255.65 million, a P/E ratio of -4.08 and a beta of 1.55. The company has a quick ratio of 2.47, a current ratio of 2.83 and a debt-to-equity ratio of 9.39.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.14). AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. The company had revenue of $18.41 million during the quarter, compared to the consensus estimate of $18.40 million. Equities research analysts anticipate that AVITA Medical, Inc. will post -0.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RCEL has been the subject of a number of recent research reports. Piper Sandler reissued a "neutral" rating and set a $12.00 price target (up from $9.00) on shares of AVITA Medical in a research report on Friday, November 8th. D. Boral Capital decreased their target price on shares of AVITA Medical from $25.00 to $22.00 and set a "buy" rating for the company in a report on Thursday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $21.00 target price on shares of AVITA Medical in a report on Tuesday, December 24th. Finally, Lake Street Capital decreased their target price on shares of AVITA Medical from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $17.25.

Institutional Trading of AVITA Medical

A number of large investors have recently made changes to their positions in the stock. AlphaQuest LLC grew its stake in shares of AVITA Medical by 24.7% in the fourth quarter. AlphaQuest LLC now owns 9,378 shares of the company's stock worth $120,000 after acquiring an additional 1,858 shares during the period. Russell Investments Group Ltd. grew its stake in shares of AVITA Medical by 48.0% in the fourth quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company's stock worth $92,000 after acquiring an additional 2,324 shares during the period. FMR LLC grew its stake in shares of AVITA Medical by 126.9% in the third quarter. FMR LLC now owns 4,248 shares of the company's stock worth $46,000 after acquiring an additional 2,376 shares during the period. BNP Paribas Financial Markets bought a new stake in AVITA Medical during the fourth quarter valued at approximately $38,000. Finally, Huntington National Bank bought a new stake in AVITA Medical during the third quarter valued at approximately $32,000. 27.66% of the stock is currently owned by institutional investors.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.